Neurobiology of Disease

Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates

Maryka Quik, Li Chen, Neeraja Parameswaran, Xinmin Xie, J. William Langston, and Sarah E. McCallum
The Parkinson’s Institute, Sunnyvale, California 94089

Our recent studies show that chronic oral nicotine partially protects against striatal damage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primates. To identify the cellular changes associated with this protective action, we investigated the effects of nicotine treatment on stimulus-evoked dopamine release, dopamine turnover, and synaptic plasticity in striatum from lesioned and unlesioned animals. Monkeys were chronically (6 months) treated with nicotine in the drinking water and subsequently lesioned with the dopaminergic neurotoxin MPTP (6 months) while nicotine was continued. Nigrostriatal damage increased nicotinic acetylcholine receptor (nAChR)-mediated fractional dopamine release from residual terminals, primarily through changes in α3/α6 nAChRs. In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. Long-term nicotine administration also attenuated the enhanced K+-evoked fractional dopamine release from synaptosomes of MPTP-lesioned animals, suggesting that nicotine treatment had a generalized effect on dopaminergic function. This premise was further supported by experiments showing that nicotine dosing decreased the elevated dopamine turnover that occurs after nigrostriatal damage. We next investigated changes in synaptic plasticity with lesioning and nicotine treatment. Nicotine treatment alone enhanced synaptic plasticity by lowering the threshold for long-term depression (LTD) in the corticostriatal pathway. MPTP lesioning led to a loss of LTD, a measure of short-term synaptic plasticity. In contrast, LTD was preserved in nicotine-treated lesioned animals. Thus, the present data show that the disruptions in striatal dopaminergic function after nigrostriatal damage were attenuated with chronic nicotine administration. These cellular alterations may underlie the ability of nicotine to maintain/restore normal function with nigrostriatal damage.

Key words: nicotine; Parkinson’s disease; nonhuman primates; nicotinic; dopamine; MPTP

Introduction

Epidemiological studies have repeatedly shown that smoking is associated with ~50% decreased incidence of Parkinson’s disease, a neurological disorder characterized by a loss of dopaminergic neurons in the nigrostriatal pathway (Morens et al., 1995; Allam et al., 2004; Olanow, 2004; Samii et al., 2004; Schapira, 2004). Although the active component in cigarette smoke is not yet known, accumulating evidence points to a role for nicotine as a contributor to this apparent neuroprotective effect (O’Neill et al., 2002; Quik, 2004). Support for this possibility stems from studies showing that exposure of cultured cells to nicotine attenuates cellular degeneration (Jin et al., 2004; Papke et al., 2004; Zhou et al., 2004), including damage induced by neurotoxins that selectively destroy dopamine neurons (Jeyarasasingam et al., 2002). In vivo studies also indicate that nicotine protects against nigrostriatal damage, although inconsistencies have been observed in rodent models that may relate to the specific experimental paradigms used, species, or other factors (Janson et al., 1992; Hadjiconstantinou et al., 1994; Costa et al., 2001; Ryan et al., 2001; O’Neill et al., 2002; Parain et al., 2003; Quik, 2004). To more closely resemble the human condition, nonhuman primates were chronically administered nicotine in the drinking water and subsequently lesioned with several small doses of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce slow nigrostriatal damage (Quik et al., 2005b). Nicotine treatment led to a partial return of tyrosine hydroxylase, the dopamine transporter, vesicular monoamine transporter, dopamine levels, and nicotinic acetylcholine receptors (nAChRs) in striatum of lesioned primates compared with lesioned animals not receiving nicotine (Quik et al., 2005b). These data demonstrate that nicotine dosing improves biochemical/anatomical markers of striatal dopaminergic nerve terminal integrity in lesioned monkeys compared with animals not receiving nicotine.

The present experiments were done to determine the functional consequences of chronic nicotine exposure on nigrostriatal damage at the cellular level. To approach this, we investigated the effect of nicotine administration on dopamine release and turnover in the striatum of unlesioned and lesioned animals treated...
with and without nicotine. These measures were selected because previous work had shown that nigrostriatal damage increased both dopamine turnover (Hornykiewicz, 1998, 2001) and evoked dopamine release from residual dopaminergic terminals (Zigmond et al., 1984, 1990; Zigmond, 1997; McCallum et al., 2006a). Moreover nicotine administration is well known to modulate nAChR function, including evoked dopamine release from striatum, both after acute and chronic exposure (Buissone and Bertrand, 2002; Gentry and Lukas, 2002; Dajas-Bailador and Wonnacott, 2004; Wonnacott et al., 2005).

To further elucidate the mechanism involved in this phenomenon, we investigated the effect of nicotine treatment on long-term depression (LTD) in corticostriatal slices from unlesioned and MPTP-lesioned primates. Previous work had shown that synaptic plasticity, as measured using LTD, is severely impaired after dopaminergic denervation in rodents (Calabresi et al., 1992a,b; Centonze et al., 1999, 2001). In the present study, we tested whether nicotine administration prevented this loss of plasticity in corticostriatal slices from MPTP-lesioned primates.

Materials and Methods

Animals. Adult female squirrel monkeys (Saimiri sciureus) were purchased either from Osage Research Primates (Osage Beach, MO) or the University of South Alabama (Mobile, AL). Animals were housed separately in a room with a 13/11 h light/dark cycle and were fed once daily with ad libitum access to water. A standard 4 week quarantine period was initiated upon arrival. Before treatment, the monkeys were allowed to acclimate to the home environment for 1 month before treatment. Animals were then randomly assigned to one of four treatment groups: control (with 0.5 mg/ml phenytoin sodium), followed by 2.2 ml/kg (i.v.) of the euthanasia solution (390 mg/ml sodium pentobarbital [1.5 mg/kg, s.c.] over a 6 month period at 2 month intervals with nicotine treatment continued until 24 h before death. The animals were killed by either Newman–Keuls or Bonferroni’s test, respectively, using a level of 0.05 was considered significant.

Electrophysiology. After dissection, the 2 mm coronal monkey brain slice at level A13–A12 was bisected at the level of the internal capsule, and the portion containing the putamen was quickly placed in ice-cold, oxygenated buffer containing the following (in mM): 248 sucrose, 1.5 KCl, 6.0 MgSO4, 1.0 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, and 11 glucose, pH 7.4. It was then cut into 300–350 μm slices, using a vibratome in a plane to include cortex and putamen such that the corticostriatal connections between these two regions were maintained (Chen et al., 2008). The slices were incubated at room temperature for 30 min in oxygenated artificial CSF (ACSF), pH 7.4, containing the following (in mM): 124 NaCl, 2.5 KCl, 1.5 MgSO4, 2.0 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, and 11 glucose. A slice was transferred to the recording chamber and perfused with ACSF at 35°C. Extracellular striatal field potentials were then recorded from the dorsal putamen as described previously (Chen et al., 2006) by bipolar stimulation (0.1 Hz; 100 μs 6–8 V) of the cerebellar cortex or white matter between the cortex and putamen. Synaptic plasticity was determined by comparing average peak amplitude or slope of the striatal field potentials before and after high-frequency stimulation (HFS) (100 Hz; 100 μs; 14 V pulses). The quantitative data are expressed as a percentage of baseline, which represents the average amplitude of evoked field potentials, recorded after stabilization of the response 10–20 min before tetanic HFS.

Data analyses. [3H]Dopamine release was quantitated as previously described (McCallum et al., 2005). Rmax and EC50 values were obtained from dose–response curves by fitting data to a nonlinear regression equation in SigmaPlot 2001 for Windows (SPSS, Chicago, IL). Fractional release was determined by dividing release for a particular sample by the dopamine transporter value to obtain a measure of release from residual dopaminergic terminals as reported previously (Snyder et al., 1990). Statistical analyses were done using one- or two-way ANOVA followed by either Newman–Keuls or Bonferroni’s post hoc test, respectively, using GraphPad Prism (San Diego, CA). All values are expressed as the mean ± SEM of the indicated number of animals. A level of p < 0.05 was considered significant.
Table 1. Effect of nicotine and/or MPTP treatments on the striatal dopamine transporter

<table>
<thead>
<tr>
<th>Striatal region</th>
<th>Treatment group</th>
<th>Number of animals</th>
<th>DAT (ncI/mg tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial caudate</td>
<td>Control</td>
<td>7</td>
<td>35.3 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>Nicotine*</td>
<td>6</td>
<td>41.8 ± 3.9</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>7</td>
<td>21.9 ± 2.9*</td>
</tr>
<tr>
<td></td>
<td>Nicotine + MPTP</td>
<td>6</td>
<td>25.8 ± 3.4*</td>
</tr>
<tr>
<td>Lateral caudate</td>
<td>Control</td>
<td>7</td>
<td>32.8 ± 0.7</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>6</td>
<td>34.7 ± 2.7</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>7</td>
<td>8.5 ± 1.2*</td>
</tr>
<tr>
<td></td>
<td>Nicotine + MPTP</td>
<td>6</td>
<td>13.6 ± 3.2*</td>
</tr>
<tr>
<td>Ventral putamen</td>
<td>Control</td>
<td>7</td>
<td>30.2 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>6</td>
<td>34.3 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>7</td>
<td>17.7 ± 2.5*</td>
</tr>
<tr>
<td></td>
<td>Nicotine + MPTP</td>
<td>6</td>
<td>23.2 ± 3.1*</td>
</tr>
<tr>
<td>Dorsal putamen</td>
<td>Control</td>
<td>7</td>
<td>33.5 ± 1.1</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>5</td>
<td>34.5 ± 1.4</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>7</td>
<td>7.2 ± 1.2*</td>
</tr>
<tr>
<td></td>
<td>Nicotine + MPTP</td>
<td>6</td>
<td>12.4 ± 3.0*</td>
</tr>
</tbody>
</table>

Monkeys were chronically administered nicotine in the drinking water and subsequently administered MPTP as described in Materials and Methods. Dopamine transporter autoradiography was done on striatal sections using [125I]-RTI-121. DAT, dopamine transporter. Significance of difference from control, *p < 0.001.

Table 2. Effect of nicotine and/or MPTP treatments on evoked dopamine release levels

<table>
<thead>
<tr>
<th>Striatal region</th>
<th>Treatment group</th>
<th>Total</th>
<th>α4*</th>
<th>α6*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial caudate</td>
<td>Control</td>
<td>5794</td>
<td>382</td>
<td>789</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>508</td>
<td>394</td>
<td>877</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>2826</td>
<td>194</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>2383</td>
<td>192</td>
<td>205</td>
</tr>
<tr>
<td>Lateral caudate</td>
<td>Control</td>
<td>5024</td>
<td>497</td>
<td>306</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>4522</td>
<td>181</td>
<td>443</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>2826</td>
<td>174</td>
<td>205</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>2383</td>
<td>174</td>
<td>205</td>
</tr>
<tr>
<td>Ventral putamen</td>
<td>Control</td>
<td>7287</td>
<td>602</td>
<td>167</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>3820</td>
<td>194</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>8373</td>
<td>709</td>
<td>622</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>6102</td>
<td>196</td>
<td>366</td>
</tr>
<tr>
<td>Dorsal putamen</td>
<td>Control</td>
<td>3721</td>
<td>849</td>
<td>799</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>3155</td>
<td>858</td>
<td>709</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>2589</td>
<td>575</td>
<td>574</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>1814</td>
<td>399</td>
<td>284</td>
</tr>
</tbody>
</table>

Monkeys were given nicotine in the drinking water and subsequently administered MPTP, with nicotine treatment continued until the animals were killed. Nicotine-evoked dopamine release (Rmax) was then determined in the absence (Total) and presence of 50 nM α-conotoxinMII (α4* nACHr component) or 100 nM α-conotoxinMII (α6* nACHr component). The percentage release measured in the presence of α-conotoxinMII was defined as the α6* nACHr component. Each value represents the mean ± SEM of five to seven animals. Values were used to calculate nicotine-evoked fractional [3H]dopamine release or release from residual terminals, which represents maximal evoked dopamine release (Rmax) divided by dopamine transporter values (Total) as described previously (Snyder et al., 1990).

Results

Animal model

For these studies, we provided nicotine to the monkeys in the drinking water, as this approach has the advantage that administration is pulsatile because animals drink sporadically throughout the day and yet chronic because treatment is provided over many months. As previously reported, this nicotine-dosing regimen resulted in plasma nicotine levels of 12.6 ± 1.3 ng/ml (n = 12) and cotinine levels of 370 ± 47 ng/ml (n = 12), which are within the range of those in the plasma of smokers (Quik et al., 2005b). The chronic nicotine treatment was well tolerated; the animals appeared well on physical examination, and there were no significant differences in body weight or fluid intake among the groups (Quik et al., 2005b). The animals’ activity was also measured using a computerized activity monitor system (Togasaki et al., 2005) with no differences in total daily activity among the four treatment groups (Quik et al., 2005b).

Low-dose MPTP (1.5 mg/kg) was administered subcutaneously three times at 2 month intervals to generate a relatively slow prolonged lesion. We used dopamine transporter autoradiography ([125I]-RTI-121) as an index of dopaminergic damage, because this measure may reflect functional transporter sites at the terminal (Quik et al., 2001). MPTP treatment led to significant 40–80% decreases in dopamine transporter binding in the different striatal regions (Table 1). Two-way ANOVA yielded an overall significant main effect of MPTP lesioning (p < 0.001) in every region, consistent with previously reported measurements of striatal dopamine transporter using Western blots (Quik et al., 2005b). There was also a significant main effect of nicotine dosing (p < 0.05) in each striatal region, with no significant interaction between MPTP and nicotine treatment.

Nicotine treatment normalizes MPTP-induced increases in fractional nACHr-mediated dopamine release in striatum

Experiments were next done to determine the effect of chronic nicotine in the drinking water on nACHr-evoked dopamine release from striatal synaptosomes of unlesioned and lesioned monkeys (Table 2). Because MPTP treatment resulted in significant nigrostriatal damage or loss of dopamine terminals as reflected by a decline in the dopamine transporter (Table 1), we determined nicotine-evoked fractional [3H]dopamine release from synaptosomes prepared from striatum of unlesioned and lesioned monkeys. To measure fractional release or release from residual terminals, maximal nACHr-evoked dopamine release (Rmax) was then determined in the absence (Total) and presence of 50 nM α-conotoxinMII (α4* nACHr component). The percentage release measured in the presence of α-conotoxinMII was defined as the α6* nACHr component. Each value represents the mean ± SEM of five to seven animals. These values were used to calculate nicotine-evoked fractional α4*/α6*-nACHr-mediated dopamine release or release from residual terminal, which represents maximal evoked dopamine release (Rmax) divided by dopamine transporter values (Total) as described previously (Snyder et al., 1990).

Nicotine treatment has a predominant effect on α3*/α6* nACHr-mediated fractional dopamine release in striatum

nACHr-mediated dopamine release in the primate striatum is primarily mediated by α3*/α6* and α4* nACHr subtypes (McCullum et al., 2005), with the asterisks indicating the presence of other subunits in the receptor complex. To differentiate these two components of nicotine-evoked release, we used the selective α3*/α6* nACHr antagonist α-conotoxinMII to define α3*/α6* nACHr-evoked fractional release (α-conotoxinMII-sensitive) and α4* nACHr-mediated fractional release (α-conotoxinMII-resistant). The results in Figure 2 show that there was a small decline in α3*/α6* nACHr-mediated (or α-conotoxinMII-sensitive) fractional dopamine release with chronic nicotine treatment in some striatal regions as reported previously (McCullum et al., 2006b). Nigrostriatal damage significantly (p < 0.01) enhanced release in both caudate and putamen. In contrast, in lesioned monkeys treated with nicotine, a reduction was ob-
Numerous studies have shown that there are significant changes in dopamine and metabolite levels after nigrostriatal damage. In the present study, we investigated the effects of chronic nicotine treatment on dopamine turnover in monkeys with nigrostriatal damage. Monkeys were administered chronic nicotine (Nic) and/or MPTP as described previously. Nicotine-evoked [3H]dopamine release was then determined from striatal synaptosomes. Results are expressed as the total nicotinic-evoked dopamine release (R_{\text{max}}; 
\text{cpm/mg tissue}) divided by the dopamine transporter values (nCi/mg tissue). They represent the mean ± SEM of five to seven monkeys per group. Significance of difference from the control group (Con) using Bonferroni’s post hoc test, *p < 0.05; **p < 0.01. Significance of difference from the MPTP-treated group, \*p < 0.05; \**p < 0.01.

Nicotine treatment normalizes MPTP-induced increases in fractional K^{+} -evoked striatal dopamine release

Experiments were subsequently done to determine whether the effect of chronic nicotine treatment was selective for nicotine-evoked [3H]dopamine release or whether there were also compensatory changes in fractional K^{+} -evoked release. The results in Figure 4 show that nicotine treatment alone had no effect on fractional K^{+} -evoked dopamine release in unlesioned animals. In contrast, nigrostriatal damage significantly enhanced release in the ventral and dorsal putamen (\( p < 0.05 \)) only in the ventral putamen. This contrasts with the lack of change in \( \alpha 4 \) receptor-evoked release in the caudate under any condition.

Nicotine treatment normalizes MPTP-induced increases in striatal dopamine turnover

Numerous studies have shown that there are significant changes in dopamine and metabolite levels after nigrostriatal damage in...
Figure 4. Long-term nicotine treatment reduces the enhanced K⁺-evoked fractional \(^{[3]H}\) dopamine release from monkey striatal regions after nigrostriatal damage. Monkeys were chronically treated with nicotine (Nic) and/or MPTP. \(^{[3]H}\) dopamine release was then evoked from striatal synaptosomes using 20 mM K⁺. Results are expressed as the K⁺-mediated \(^{[3]H}\) dopamine release (cpm/mg tissue) divided by the dopamine transporter values (nCi/mg tissue). They represent the mean ± SEM of five to seven monkeys per group. Significance of difference from the respective control group (Con) in the same striatal region using Bonferroni’s post hoc test, \(p < 0.05\).

Table 3. Effect of nicotine and/or MPTP treatments on striatal dopamine and metabolite levels

<table>
<thead>
<tr>
<th>Striatal region</th>
<th>Treatment group</th>
<th>Concentration (ng/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DOPAC</td>
<td>HVA</td>
</tr>
<tr>
<td>Medial caudate</td>
<td>Control</td>
<td>89.64 ± 2.84</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>102.6 ± 7.57</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>29.12 ± 5.25</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>54.17 ± 8.13</td>
</tr>
<tr>
<td>Lateral caudate</td>
<td>Control</td>
<td>97.81 ± 6.04</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>99.57 ± 9.29</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>12.49 ± 5.47</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>26.89 ± 12.01</td>
</tr>
<tr>
<td>Ventral putamen</td>
<td>Control</td>
<td>115.8 ± 11.95</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>127.4 ± 13.24</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>14.92 ± 4.97</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>42.27 ± 7.10</td>
</tr>
<tr>
<td>Dorsal putamen</td>
<td>Control</td>
<td>109.9 ± 12.61</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>127.5 ± 11.33</td>
</tr>
<tr>
<td></td>
<td>MPTP</td>
<td>2.46 ± 0.57</td>
</tr>
<tr>
<td></td>
<td>MPTP + nicotine</td>
<td>9.82 ± 4.46</td>
</tr>
</tbody>
</table>

Animals were given nicotine in the drinking water and subsequently administered MPTP, with nicotine treatment continued until the animals were killed. Brain dopamine and metabolite levels were then measured in the different striatal areas. Each value represents the mean ± SEM of five to seven animals. The results were analyzed using a two-way ANOVA followed by Bonferroni’s post hoc test. Significance of difference from control, \(p < 0.01\).

Figure 5. Chronic nicotine treatment reduces the enhanced dopamine turnover observed in monkey striatum after nigrostriatal damage. Monkeys were administered chronic nicotine (Nic) and/or MPTP as described previously. Dopamine, DOPAC, and HVA were then measured in the different striatal regions, and dopamine turnover (dopamine/DOPAC plus HVA) was quantified. Values represent the mean ± SEM of five to seven monkeys per group. Significance of difference from the control group (Con) using Bonferroni’s post hoc test, \(p < 0.05\); \(^*\) \(p < 0.01\).

Chronic nicotine treatment reduces the threshold for corticostriatal LTD induction in unlesioned and MPTP-lesioned monkeys

Corticostriatal slices for electrophysiological recording were prepared from brain sections at level A12–A13. Cortical stimulation-evoked field potentials (EFPs) were evoked by bipolar stimulation of projection fibers in ACSF containing Mg²⁺. Initial studies to establish control parameters for in vitro electrophysiological recording in monkey slices showed that the amplitude of EFPS was dependent on stimulus strength (our unpublished observations). Subsequent tetanus stimulation (100 Hz; 100 µs; 14 V; 20–900 pulses) of the corticostriatal pathway induced a LTD, which is the predominant change in plasticity observed using physiological concentrations of Mg²⁺ (Centonze et al., 2001; Pisani et al., 2005). Corticostriatal LTD recordings were obtained from the majority (7 of 10) of control monkeys, with representative data from one monkey depicted in Figure 6A. The LTD induction threshold was defined as the minimum number of HFS pulses necessary to generate a significant long-term (>20 min) decrease in EFP amplitude. In contrast, tetanus stimulation failed to induce LTD in slices from any MPTP-lesioned monkey (0 of 3) (Fig. 6B), consistent with studies in rodents (Calabresi et al., 1992a; Centonze et al., 1999, 2001; Chen et al., 2006). Stimulation of the corticostriatal pathway in slices from animals chronically treated with nicotine (Fig. 6C) also resulted in LTD in three

Parkinson’s disease and in animal models (Zigmond et al., 1990; Hornykiewicz, 2001). To determine the effect of chronic nicotine treatment with nigrostriatal damage, dopamine, DOPAC, and HVA were determined in monkey striatum (Table 3). The results show that these measures were reduced with nigrostriatal damage in every region of striatum (\(p < 0.01\)). Nicotine treatment had no effect on dopamine levels in unlesioned animals, although there was a significant main effect of nicotine (\(p < 0.01\)) in lesioned animals as shown previously (Quik et al., 2005b).

The ratio of dopamine levels to those of the dopamine metabolites DOPAC and HVA (dopamine/DOPAC plus HVA), or dopamine turnover, was subsequently calculated (Fig. 5) as a measure of dopamine clearance by remaining dopaminergic neurons (Zigmond et al., 1990; Hornykiewicz, 2001). An increase was observed in dopamine turnover in all subregions of striatum from lesioned monkeys, with the greatest increases (\(p < 0.01\)) in the lateral caudate and dorsal putamen, that is, the regions with the greatest dopaminergic loss. Dopamine turnover rates in animals treated with nicotine and MPTP were significantly lower than in animals treated only with MPTP in medial caudate (\(p < 0.05\)), lateral caudate (\(p < 0.05\)), and ventral putamen (\(p < 0.01\)), although not dorsal putamen.
of the four treated animals. In nicotine-treated MPTP-lesioned animals, a robust LTD was observed (Fig. 6D) in four of the five.

The combined results from the monkeys in each group exhibiting LTD is depicted in Figure 7. The results show that chronic nicotine treatment significantly reduced the threshold for LTD induction in both unlesioned and MPTP-lesioned monkeys. These data suggest that chronic oral nicotine treatment enhances synaptic plasticity in both unlesioned and MPTP-lesioned monkeys.

**Discussion**

The present experiments are the first to show that chronic oral nicotine normalizes aberrant striatal function that occurs as a consequence of nigrostriatal damage. To approach this, we evaluated several measures of striatal activity. These include dopamine release, dopamine turnover, and synaptic plasticity, with the latter defined by changes in LTD. We first determined nAChR-mediated dopamine release (Wonnacott, 1997), a measure directly linked to nicotine treatment. Chronic nicotine dosing normalized the lesion-induced increase in nicotine-evoked release from residual dopamine terminals in monkey striatum. Unexpectedly, nicotine treatment also reduced K+ evoked fractional dopamine release and dopamine turnover, which were both elevated as a result of nigrostriatal damage (Zigmond et al., 1984, 1990; Zigmond, 1997; Hornykiewicz, 1998, 2001; McCallum et al., 2006a). These combined data indicate that nicotine treatment not only restores functional measures directly associated with nAChR stimulation but also results in a generalized return of striatal function to normal after chronic nigrostriatal damage.

We also investigated the effect of nicotine treatment on striatal plasticity in both unlesioned and lesioned animals because changes in synaptic strength are implicated in motor function (Pisani et al., 2005). Repetitive stimulation of the corticostriatal pathway can induce long-term potentiation and LTD, with the direction of the change in plasticity dependent on the level of membrane depolarization and the select neuronal systems activated (Pisani et al., 2005). Under the present experimental conditions (ACSF containing Mg2+), the synaptic change was LTD as previously observed in the rodent corticostriatal pathway (Calabresi et al., 1992a,b; Centonze et al., 1999, 2001; Chen et al., 2006). Interestingly, the synaptic plasticity lost with nigrostriatal damage was preserved in lesioned animals with chronic nicotine treatment, that is, LTD was restored. Because synaptic plasticity in basal ganglia motor circuits has been proposed as a neuronal mechanism underlying motor learning and memory (Pisani et al., 2005), these data support the idea that chronic nicotine administration helps maintain/restore normal nigrostriatal function.

In the current study, nicotine was administered before and during the development of nigrostriatal damage. This regimen was selected because our intent was to determine whether the
nicotine in tobacco might account, at least in part, for the decreased incidence of Parkinson’s disease with smoking. With the current nicotine-dosing schedule, striatal function may have normalized because nicotine improved function after injury and/or reduced the MPTP-induced nigristrial degeneration. This damage was most likely attributable to the neurotoxic effects of MPTP, but may also have occurred because of compensatory increases in dopamine turnover and fractional dopamine release after nigristrial damage (Zigmond et al., 1990; Zigmond, 1997; Elsworth et al., 2000; McCallum et al., 2006a). Elevated dopamine levels have been shown to increase production of reactive oxygen species such as peroxides, superoxides, and hydroxyl radicals and dopamine quinones in residual dopamine terminals (Halliwell, 1992; Hastings et al., 1996; Blum et al., 2001). These cytotoxic products may augment the existing nigristrial damage (Rosenberg, 1988; Masserano et al., 1996; McLaughlin et al., 1998; Ber- man and Hastings, 1999).

Nicotine may exert a protective action against toxicity in several ways. It may diminish elevated dopaminergic function through an interaction at nAChRs. Two primary subtypes in the primate striatum include α3/α6* and α4* nAChRs, with the asterisks indicating the presence of additional subunits in the receptor complex (Quik et al., 2005a). These form pentameric heteromeric receptors that mediate dopamine release in the striatum (Gotti and Clementi, 2004), with ~70% release evoked by stimulation of α3*/α6* nAChRs and the remainder (30%) by α4* receptors (McCallum et al., 2005). Chronic nicotine administration decreases α3*/α6* nAChRs and is well known to desensitize α4* subtypes, both of which may result in alterations in neuronal transduction mechanisms (Wonacott, 1997; Ginatiullin et al., 2005; Lai et al., 2005; McCallum et al., 2006b). Changes in intracellular calcium probably represent an important initial event because nAChRs flux calcium and nAChR-evoked function is calcium dependent (O’Neill et al., 2002; Dajas-Bailador and Wonacott, 2004; Quik, 2004; Wonacott et al., 2005). Diverse downstream pathways and processes, such as phosphorylation, may be activated to lead to alterations in caspases, kinases, CREB (cAMP response element-binding protein), apoptotic signaling, the nitric oxide/cGMP pathway, and others (Fedele et al., 1998; Garrido et al., 2001; Brunzell et al., 2003; Mai et al., 2003; Jin et al., 2004).

Activation of these signaling mechanisms may subsequently lead to neuroprotection through a variety of mechanisms including changes in synaptic plasticity. For instance, in the present studies, we observed that chronic nicotine treatment facilitated corticostriatal synaptic plasticity or LTD, a function dependent on nAChR-evoked dopamine release (Partridge et al., 2002). The glutamatergic corticostriatal pathway is the major excitatory input to the basal ganglia (DeLong, 1990; Partridge et al., 2002; Kolomiets et al., 2003). Chronic nicotine treatment may attenuate neuronal damage by reducing glutamatergic excitotoxicity in the striatum through an enhanced LTD.

Nicotine may also enhance/restore striatal dopaminergic nerve terminal integrity and function through a trophic action. nAChR activation is well known to stimulate neuronal growth (Chan and Quik, 1993; Zheng et al., 1994; Erskine and McCaig, 1995; Owen and Bird, 1995; Coronas et al., 2000; Pugh and Margiotta, 2000). Although the mechanisms are unclear, nicotine may stimulate trophic factors such as basic fibroblast growth factor, which are elevated in rodents after chronic nicotine treatment (Belluardo et al., 2000).

In addition, nicotine may act through receptor-independent mechanisms. These include a direct antioxidant effect possibly through lipid peroxidation and/or by scavenging reactive oxygen species such as peroxides (Soto-Otero et al., 2002; Cormier et al., 2003). Nicotine also appears to compete with NADH to attenuate mitochondrial respiratory control (Cormier et al., 2003), and to reduce mitochondrial swelling and cytochrome c release from mitochondria in the presence of nAChR blockers (Xie et al., 2005). In addition, liver metabolizing enzymes such as cytochrome P450 are induced by nicotine (Tyndale, 2003; Hukkanen et al., 2005).

It is unlikely that nicotine had a direct effect on MPTP biodistribution, because previous studies had shown that nicotine only affected dopaminergic measures in the striatum and not dopaminergic cell number in the substantia nigra (Quik et al., 2005b). As well, the activity of monoamine oxidase, the enzyme responsible for the conversion of MPTP to the active metabolite MPP+, was not different in animals treated with or without nicotine (our unpublished observation).

The almost complete restoration of striatal function, that is, fractional dopamine release, dopamine turnover, and LTD, after nicotine treatment was unexpected when compared with the much smaller reversal (~20%) in striatal dopaminergic markers (Quik et al., 2005b). Tyrosine hydroxylase, the dopamine transporter, vesicular monoamine transporter and dopamine levels were still reduced >50% after nigristrial damage in nicotine-treated monkeys, although some functional measures were almost normal. This discrepancy may relate to multiple adaptive mechanisms that arise after nigristrial damage. These include other presynaptic dopaminergic changes (Zigmond et al., 1990; Zigmond, 1997; Hornykiewicz, 2001), as well as alterations in postsynaptic mechanisms such as dopamine receptor supersensitivity and in tachykinin, enkephalinergic, GABAergic, and cholinergic function (Lee et al., 1978; Todd et al., 1996; Zigmond, 1997; Bezdard et al., 2001, 2003; Meissner et al., 2003).

The primate striatum is anatomically diverse and receives differential dopaminergic inputs from discrete regions in the substantia nigra to result in ventromedial to dorsolateral innervation gradients in the striatum. These gradients are associated with distinct patterns of striatal degeneration with nigristrial damage, with more severe dopaminergic losses in dorsolateral compared with ventromedial regions and greater declines in the putamen than caudate in animal models and Parkinson’s disease (Parent et al., 1983; Hirsch et al., 1988; Kemel et al., 1989; Gibb et al., 1990; Graybiel et al., 1990; Fearnley and Lees, 1991; Parent and Lavoie, 1993). The present data also exhibit ventromedial to dorsolateral gradients in MPTP-lesioned animals with a more pronounced neurodegeneration in the putamen than caudate. Moreover, the functional restoration with nicotine treatment parallels these morphological gradients.

The finding that nicotine administration ameliorates function in monkeys with nigristrial degeneration raises the question whether it may be of therapeutic benefit. To date, administration of the nicotine patch and/or gum has yielded conflicting results, with some studies reporting small improvements in motor and cognitive deficits and others no effect or a decline (Ishikawa and Miyatake, 1993; Fagerstrom et al., 1994; Ebersbach et al., 1999; Kelton et al., 2000; Vieregge et al., 2001; Lemay et al., 2004). Drawbacks of these studies include the limited number of subjects and very short duration (2–4 weeks). The current experimental design would suggest that longer treatment periods with nicotine are required. The use of nicotine for Parkinson’s disease therapy therefore requires further study.

In summary, the present results show that chronic nicotine treatment tends to normalize lesion-induced overactivity of the
nigrostriatal pathway, with an attenuation of the enhanced striatal dopamine turnover and evoked dopamine release. In addition, nicotine treatment preserves synaptic plasticity that is lost with nigrostriatal damage. These results suggest that long-term nicotine administration has potential as a treatment strategy to either protect against or restore dopaminergic terminal function in Parkinson’s disease, a chronic disorder with progressive neurodegeneration.

References
Lai A, Parmasewaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, Quik et al. • Nicotine Normalizes Striatal Function

J. Neurosci., April 26, 2006 • 26(17):4681–4689


McCallum SE, Parameswaran N, Bordia T, Fan H, Tyndale RF, Langston JW, McIntosh JM, Quik M (2006b) Increases in α4* but not α3β* α6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem 96:1028–1041.


Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, Clementi F, Gotti C (2005a) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or α-DOPA. Mol Pharmacol 67:32–41.


